GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,485.60p
   
  • Change Today:
      24.60p
  • 52 Week High: 2,263.00p
  • 52 Week Low: 1,296.00p
  • Currency: UK Pounds
  • Shares Issued: 4,094.68m
  • Volume: 7,774,368
  • Market Cap: £60,831m
  • RiskGrade: 129

Second-line use of GSK cancer drug restricted

By Abigail Townsend

Date: Friday 11 Nov 2022

LONDON (ShareCast) - (Sharecast News) - The second-line application of a GSK cancer treatment will be limited following a request by the US regulators, the drugs giant said on Friday.
The first-line application of Zejula - a maintenance treatment for ovarian, fallopian tube and peritoneal cancer for patients who have had a response to platinum-based chemotherapy - remains unchanged, however.

London-listed GSK said the US Food and Drug Administration had requested that the second line application be restricted to specific patients only, those with deleterious or suspected deleterious germline BRCA mutations.

The decision followed a review by the FDA of the final overall survival data from a phase III trial of Zejula.

Zejula is an oral, once-daily PARP inhibitor which is currently being evaluated across multiple trials. "GSK is building a robust clinical development programme by assessing activity across multiple tumour types and evaluating several potential combinations of Zejula with other therapeutics," the blue chip noted.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,485.60p
Change Today 24.60p
% Change 1.68 %
52 Week High 2,263.00p
52 Week Low 1,296.00p
Volume 7,774,368
Shares Issued 4,094.68m
Market Cap £60,831m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
58.29% below the market average58.29% below the market average58.29% below the market average58.29% below the market average58.29% below the market average
82.76% above the sector average82.76% above the sector average82.76% above the sector average82.76% above the sector average82.76% above the sector average
Price Trend
40.31% below the market average40.31% below the market average40.31% below the market average40.31% below the market average40.31% below the market average
25.81% above the sector average25.81% above the sector average25.81% above the sector average25.81% above the sector average25.81% above the sector average
Income
67.69% above the market average67.69% above the market average67.69% above the market average67.69% above the market average67.69% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
51.89% below the market average51.89% below the market average51.89% below the market average51.89% below the market average51.89% below the market average
75% below the sector average75% below the sector average75% below the sector average75% below the sector average75% below the sector average

What The Brokers Say

Strong Buy 2
Buy 6
Neutral 14
Sell 1
Strong Sell 2
Total 25
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q4 Q3
Ex-Div 23-Feb-23 17-Nov-22
Paid 13-Apr-23 12-Jan-23
Amount 13.75p 13.75p

Trades for 07-Feb-2023

Time Volume / Share Price
16:45 153 @ 1,485.40p
16:45 153 @ 1,485.40p
16:45 6,466 @ 1,485.40p
16:45 6,466 @ 1,485.40p
16:35 1,000 @ 1,485.60p

GSK Key Personnel

CEO Emma Walmsley
CFO Iain Mackay

Top of Page